392 related articles for article (PubMed ID: 16220085)
1. Efficacy, tolerability and pharmacokinetics of two nelfinavir-based regimens in human immunodeficiency virus-infected children and adolescents: pediatric AIDS clinical trials group protocol 403.
King JR; Nachman S; Yogev R; Hodge J; Aldrovandi G; Hughes MD; Chen J; Wiznia A; Damle B; Acosta EP
Pediatr Infect Dis J; 2005 Oct; 24(10):880-5. PubMed ID: 16220085
[TBL] [Abstract][Full Text] [Related]
2. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic evaluation and short-term activity of stavudine, nevirapine, and nelfinavir therapy in HIV-1-infected adults.
Skowron G; Leoung G; Hall DB; Robinson P; Lewis R; Grosso R; Jacobs M; Kerr B; MacGregor T; Stevens M; Fisher A; Odgen R; Yen-Lieberman B
J Acquir Immune Defic Syndr; 2004 Apr; 35(4):351-8. PubMed ID: 15097151
[TBL] [Abstract][Full Text] [Related]
4. Analysis of human immunodeficiency virus type 1 drug resistance in children receiving nucleoside analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir (Pediatric AIDS Clinical Trials Group 377).
Eshleman SH; Krogstad P; Jackson JB; Wang YG; Lee S; Wei LJ; Cunningham S; Wantman M; Wiznia A; Johnson G; Nachman S; Palumbo P
J Infect Dis; 2001 Jun; 183(12):1732-8. PubMed ID: 11372025
[TBL] [Abstract][Full Text] [Related]
5. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
6. Nelfinavir pharmacokinetics in stable human immunodeficiency virus-positive children: Pediatric AIDS Clinical Trials Group Protocol 377.
Floren LC; Wiznia A; Hayashi S; Jayewardene A; Stanley K; Johnson G; Nachman S; Krogstad P; Aweeka FT;
Pediatrics; 2003 Sep; 112(3 Pt 1):e220-7. PubMed ID: 12949316
[TBL] [Abstract][Full Text] [Related]
7. A prospective, 96-week study of the impact of Trizivir, Combivir/nelfinavir, and lamivudine/stavudine/nelfinavir on lipids, metabolic parameters and efficacy in antiretroviral-naive patients: effect of sex and ethnicity.
Kumar PN; Rodriguez-French A; Thompson MA; Tashima KT; Averitt D; Wannamaker PG; Williams VC; Shaefer MS; Pakes GE; Pappa KA;
HIV Med; 2006 Mar; 7(2):85-98. PubMed ID: 16420253
[TBL] [Abstract][Full Text] [Related]
8. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial--PACTG 377. Pediatric AIDS Clinical Trials Group 377 Study Team.
Wiznia A; Stanley K; Krogstad P; Johnson G; Lee S; McNamara J; Moye J; Jackson JB; Mendez H; Aguayo R; Dieudonne A; Kovacs A; Bamji M; Abrams E; Rana S; Sever J; Nachman S
AIDS Res Hum Retroviruses; 2000 Aug; 16(12):1113-21. PubMed ID: 10954886
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
Lowe SH; Wensing AM; Hassink EA; ten Kate RW; Richter C; Schreij G; Koopmans PP; Juttmann JR; van der Tweel I; Lange JM; Borleffs JC
HIV Clin Trials; 2005; 6(5):235-45. PubMed ID: 16306030
[TBL] [Abstract][Full Text] [Related]
10. dNN study: stavudine, nelfinavir and nevirapine. Preliminary safety, activity and pharmacokinetic interactions.
Skowron G
Antivir Ther; 1998; 3 Suppl 4():61-2. PubMed ID: 10723513
[TBL] [Abstract][Full Text] [Related]
11. Combination therapy with stavudine (d4T) plus didanosine (ddI) in children with human immunodeficiency virus infection. The Pediatric AIDS Clinical Trials Group 327 Team.
Kline MW; Van Dyke RB; Lindsey JC; Gwynne M; Culnane M; Diaz C; Yogev R; McKinney RE; Abrams EJ; Mofenson LM
Pediatrics; 1999 May; 103(5):e62. PubMed ID: 10224206
[TBL] [Abstract][Full Text] [Related]
12. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
13. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.
Yogev R; Lee S; Wiznia A; Nachman S; Stanley K; Pelton S; Mofenson L; Fiscus S; Jimenez E; Rathore MH; Smith ME; Song LY; McIntosh K;
Pediatr Infect Dis J; 2002 Feb; 21(2):119-25. PubMed ID: 11840078
[TBL] [Abstract][Full Text] [Related]
14. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine.
Merry C; Barry MG; Mulcahy F; Ryan M; Tjia JF; Halifax KL; Breckenridge AM; Back DJ
AIDS; 1998 Jul; 12(10):1163-7. PubMed ID: 9677165
[TBL] [Abstract][Full Text] [Related]
15. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
16. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens.
Easterbrook PJ; Newson R; Ives N; Pereira S; Moyle G; Gazzard BG
J Acquir Immune Defic Syndr; 2001 Aug; 27(4):350-64. PubMed ID: 11468423
[TBL] [Abstract][Full Text] [Related]
17. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults.
Siegfried NL; Van Deventer PJ; Mahomed FA; Rutherford GW
Cochrane Database Syst Rev; 2006 Apr; 2006(2):CD004535. PubMed ID: 16625606
[TBL] [Abstract][Full Text] [Related]
18. Virologic response to nelfinavir-based regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study).
Pellegrin I; Breilh D; Montestruc F; Caumont A; Garrigue I; Morlat P; Le Camus C; Saux MC; Fleury HJ; Pellegrin JL
AIDS; 2002 Jul; 16(10):1331-40. PubMed ID: 12131209
[TBL] [Abstract][Full Text] [Related]
19. Virological and immunological responses to once-daily dosing of didanosine in combination with stavudine. AI454-143 Team.
Mobley JE; Pollard RB; Schrader S; Adler MH; Kelleher T; McLaren C
AIDS; 1999 Jul; 13(11):F87-93. PubMed ID: 10449279
[TBL] [Abstract][Full Text] [Related]
20. Increased risk of lipodystrophy when nucleoside analogue reverse transcriptase inhibitors are included with protease inhibitors in the treatment of HIV-1 infection.
van der Valk M; Gisolf EH; Reiss P; Wit FW; Japour A; Weverling GJ; Danner SA;
AIDS; 2001 May; 15(7):847-55. PubMed ID: 11399957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]